阿斯利康上季盈利逊预期 今年内公布新冠病毒疫苗後期测试数据
英国药厂阿斯利康(AstraZeneca)(AZN.US)第三季核心每股盈利为0.94美元,不及市场预期的0.98美元。按固定汇率计算产品销售增长7%,至65.2亿美元,超出预期的60.5亿美元。
阿斯利康表示,仍预计今年收入将以高单位数至低双位数增长,而核心每股盈利增长将为中至高双位数。
公司重申预计今年稍後将会公布疫苗的後期临床测试数据,在上月公布的数据显示,阿斯利康的疫苗可在老年人及年轻人中产生免疫反应,预计英国可能会在12月下旬或2021年初开始将疫苗推出市面。(mn/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.